ReShape Lifesciences Inc. (RSLS) |
|
3.08 -0.06 (-1.91%)
|
03-24 16:00 |
|
Open: |
3.11 |
Pre. Close: |
3.14 |
|
High:
|
3.29 |
Low:
|
3 |
|
Volume:
|
49,774 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:28 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.08 One year: 6.42 |
| Support: |
Support1: 2.49 Support2: 2.07 |
| Resistance: |
Resistance1: 4.35 Resistance2: 5.5 |
| Pivot: |
3.21  |
| Moving Average: |
MA(5): 3.05  MA(20): 3.49
MA(100): 7.23 MA(250): 20.79 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -0.8 |
| Stochastic oscillator: |
%K(14,3): 29.2 %D(3): 27.6 |
| RSI: |
RSI(14): 40.6 |
| 52-week: |
High: 68.5 Low: 0.56 |
| Average Vol(K): |
3-Month: 881 (K) 10-Days: 283 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RSLS ] has closed above bottom band by 41.1%. Bollinger Bands are 73.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.29 - 3.31 |
3.31 - 3.33 |
|
Low:
|
2.96 - 2.98 |
2.98 - 3 |
|
Close:
|
3.05 - 3.08 |
3.08 - 3.11 |
|
Company Description |
|
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. |
Headline News |
Thu, 23 Mar 2023
ReShape Lifesciences Announces Formation of International ... - GlobeNewswire
Wed, 22 Mar 2023
Holdings of ReShape Lifesciences Inc. (RSLS) are aligned with the ... - SETE News
Tue, 21 Mar 2023
Is ReShape Lifesciences Inc (RSLS) Stock About to Get Hot Tuesday? - InvestorsObserver
Mon, 20 Mar 2023
ReShape Lifesciences Inc.'s (RSLS) Stock: A 61.03% Annual ... - The News Heater
Wed, 15 Mar 2023
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit - StreetInsider.com
Mon, 27 Feb 2023
Is ReShape Lifesciences Inc (RSLS) Stock a Smart Investment Monday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
6.4 (%) |
|
% Held by Institutions
|
13.2 (%) |
|
Shares Short
|
19 (K) |
|
Shares Short P.Month
|
2 (K) |
Stock Financials |
|
EPS
|
-3.13 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.34 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-241.2 |
|
Return on Assets (ttm)
|
-28.6 |
|
Return on Equity (ttm)
|
-130 |
|
Qtrly Rev. Growth
|
-24.5 |
|
Gross Profit (p.s.)
|
17.26 |
|
Sales Per Share
|
23.3 |
|
EBITDA (p.s.)
|
-51.67 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-23 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
-0.99 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.31 |
|
Price to Sales
|
0.13 |
|
Price to Cash Flow
|
-0.07 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-07-24 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
